ELDN — Eledon Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404281 ·
Last close
$1.98
Market Cap
$167.23M
52W High
$4.49
52W Low
$1.35
ADV30
909,232
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -21,672,000 | -3,933,000 | 106,639,000 | 6,882,000 | 75,843,000 |
| Jun 2026 | 0 | — | -22,869,000 | -31,630,000 | 126,094,000 | 6,803,000 | 93,081,000 |
| Mar 2026 | 0 | — | -21,181,000 | -39,025,000 | 146,667,000 | 6,152,000 | 101,903,000 |
| Dec 2025 | 0 | — | -21,484,000 | -10,447,000 | 169,009,000 | 22,808,000 | 87,924,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,857,000
Investing CF
$21,136,000
Financing CF
$53,783,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.94
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-471,858,000
Inventory
—
Receivables
$427,000
ST Investments
$81,953,000
EBIT TTM
$-84,604,000
Pretax Income TTM
$-98,526,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -83,251,000 | -45,617,000 | 169,009,000 | 87,924,000 | 81,085,000 | -62,341,000 |
| Dec 2024 | 0 | -70,577,000 | -36,184,000 | 177,405,000 | 114,959,000 | 62,446,000 | -47,271,000 |
| Dec 2023 | 0 | -43,000,000 | -116,537,000 | 89,066,000 | 81,858,000 | 7,208,000 | -39,527,000 |
| Dec 2022 | 0 | -39,780,000 | -87,966,000 | 92,793,000 | 8,610,000 | 84,183,000 | -28,424,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-98,561,000
OpCashFlow TTM
—
Assets (Latest)
$126,094,000
Forward EPS
$-0.77
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.03 · call volume: 11 · put volume: 70Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORMP | ORAMED PHARMACEUTICALS INC. | $168.29M | $3.87 | — |
| KRRO | Korro Bio, Inc. | $169.10M | $12.32 | — |
| IFRX | InflaRx N.V. | $169.47M | $1.15 | — |
| YARW | Yarrow Bioscience, Inc. | $163.04M | $14.21 | — |
| PYXS | Pyxis Oncology, Inc. | $172.24M | $1.44 | — |
News headlines (Yahoo Finance, 1h cache)
Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 21:35 · Yahoo
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology
2026-10-26 11:00 · Yahoo
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
2026-10-05 20:05 · Yahoo
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
2026-09-09 11:00 · Yahoo
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:05 · Yahoo
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
2026-06-25 11:00 · Yahoo
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
2026-06-22 11:00 · Yahoo
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:05 · Yahoo
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
2026-05-27 11:55 · Yahoo
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
2026-06-08 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.